about the author

Amber Tong

amber@endpointsnews.com @AmberTongPW
Amber Tong on LinkedIn

author articles

Find­ing a win­ner in VX-445, Ver­tex hus­tles CF com­bo to reg­u­la­tors on both sides of At­lantic

7 years ago
R&D

Se­quoia helps fu­el Whole Bio­me's planned launch for 'med­ical pro­bi­otic­s' in $35M Se­ries B

7 years ago
Financing

No­var­tis bur­nish­es prospects for its big asth­ma drug with pos­i­tive PhI­II da­ta from a sim­i­lar treat­ment

7 years ago
R&D

Ready to har­vest its PD-L1, Al­pham­ab re­loads with $60M to nur­ture the bis­pe­cif­ic patch

7 years ago
Financing
China

IPO boom: An­ti­body ex­perts at Gen­mab out­line glob­al am­bi­tion in pitch for $500M

7 years ago
Financing

‘I was shocked’: Con­tro­ver­sy brews at Emory af­ter promi­nent Chi­nese neu­ro­sci­en­tists are oust­ed over dis­clo­sure ...

7 years ago
China

Ideaya wraps $50M IPO to fu­el clin­i­cal dri­ve on syn­thet­ic lethal­i­ty

7 years ago
Financing

Novo­cure bags mesothe­lioma nod for elec­tric fields can­cer ther­a­py with some lim­i­ta­tions

7 years ago
Pharma

A new in­ter­leukin tar­get for NASH spawns Sin­ga­pore­an biotech steered by well known play­ers

7 years ago
Startups
Discovery

Dai­ichi Sankyo re­port­ed­ly sell­ing OTC unit for $900M in piv­ot to on­col­o­gy — but com­pa­ny says it's 'in­cor­rec­t'

7 years ago
Pharma

Bi­cy­cle rais­es $61M in down­sized IPO, join­ing fel­low biotechs on Nas­daq who have hauled in $1.6B col­lec­tive­ly

7 years ago
Financing

Af­fimed hangs on­to Genen­tech al­liance af­ter drop­ping strand­ed PhI pro­gram as CSO ex­its

7 years ago
R&D

No­var­tis drums up an­tic­i­pa­tion for block­buster-to-be with PhII da­ta on asth­ma drug, beat­ing Ad­vair in head-to-head

7 years ago
R&D

Thanks to Supreme Court de­ci­sion, Mer­ck gets an­oth­er chance to throw out Fos­amax claims

7 years ago
Pharma

PhI­II set­back mars Oc­u­lar's glau­co­ma drug/de­vice, though com­pa­ny re­mains 'en­cour­aged' by da­ta break­down

7 years ago
R&D

Ad­di­tion­al back­ing arms Schrödinger with $110M in first ven­ture round — shin­ing a spot­light on its own pipeline

7 years ago
Financing

As UK biotech gains steam, Syn­cona launch­es new Treg play­er while Cam­bridge spin­out ex­pands Se­ries A

7 years ago
Financing
Startups

EMA im­pos­es for­mal lim­it on Xel­janz pre­scrip­tion as reg­u­la­tors con­tin­ue to re­view safe­ty con­cerns

7 years ago
Pharma

All in on nov­el tar­get GSK-3β, Ac­tu­ate Ther­a­peu­tics rais­es $21M+ to bankroll am­bi­tious PhI/II

7 years ago
Financing

Can a lit­tle known drug in As­traZeneca's pipeline make a come­back as a PARP add-on? Yale sci­en­tists ex­plain how

7 years ago
Discovery

Gink­go BioWorks picks up an­tibi­otics ef­fort with Roche where Warp Dri­ve Bio left off

7 years ago
R&D

Ver­tex wa­gers $70M on Kymera and its new fas­ci­na­tion with pro­tein degra­da­tion

7 years ago
R&D

Pfiz­er, Mer­ck KGaA clinch need­ed ap­proval for Baven­cio, di­rect­ly com­pet­ing against Keytru­da in kid­ney can­cer

7 years ago
Pharma

Dai­ichi Sankyo 'dis­ap­point­ed' as FDA ex­perts spurn AML drug but vote in fa­vor of rare tu­mor drug

7 years ago
R&D
First page Previous page 9899100101102103104 Next page Last page
A service from the Financial Times